Last checked at 29 Jan 2018 07:00
Shield Therapeutics plc
("Shield" or the "Group")
Notice of Results
London, UK, 29 January 2018: Shield Therapeutics plc (LSE:STX), a commercial stage, pharmaceutical company delivering innovative specialty pharmaceuticals to address patients' unmet medical needs, with an initial focus on addressing anaemia associated with renal and gastrointestinal disorders, announces it will report its results for the year ended 31 December 2017 on Wednesday, 28 February 2018.
Carl Sterritt, Chief Executive Officer and Karl Keegan, Chief Financial Officer, will host a presentation and conference call for analysts at 9.30 a.m. GMT on the morning of the results in the Guildhall Room at 85 Gresham Street, London EC2V 7NQ.
-Ends-
For further information please contact:
Shield Therapeutics plc | +44 (0) 207 186 8500 |
Karl Keegan, Chief Financial Officer Fleur Wood, Director, Investor Relations
| |
Nominated Adviser and Joint Broker | +44 (0)20 3100 2222 |
Liberum Capital Limited | |
Christopher Britton/Steve Pearce
| |
Joint Broker | + 44 (0)20 7418 8900 |
Peel Hunt LLP | |
James Steel/Christopher Golden
| |
Financial PR Adviser | +44 (0)203 709 5700 |
Consilium Strategic Communications Mary-Jane Elliott/Matthew Neal | shieldtherapeutics@consilium-comms.com
|
US Investor Relations | +1 (212) 867 1762 |
Lazar Partners | |
Fern Lazar/David Carey |
About Shield Therapeutics plc
Shield is a commercial stage, pharmaceutical company delivering innovative specialty pharmaceuticals to address patients' unmet medical needs. Our clear purpose is to help our patients become people again, by enabling them to enjoy the things that make the difference in their everyday lives. The Group has a marketed product, Feraccru®, for the treatment of IDA in adult patients with IBD which has exclusive IP rights until the mid-2030's. For more information please visit www.shieldtherapeutics.com.